Efficient Loading and Sustained Delivery of Methotrexate Using a Tip-Swellable Microneedle Array Patch for Psoriasis Treatment
Source abstract
Abstract
Methotrexate (MTX), a primary treatment for moderate to severe psoriasis, is limited in clinical use due to suboptimal results and severe side effects from subcutaneous (SC) injection and oral administration. Microneedles offer a promising alternative for direct MTX delivery to targeted skin lesions, but issues such as drug wastage, dosage inaccuracy, and limited drug residence time in the lesions remain. This study introduces a tip-swellable microneedle array patch (TSMAP) using photo-cross-linked methacrylated hyaluronic acid (MeHA) and biocompatible resin for effective MTX loading and sustained delivery. A two-cast micromolding with vacuum drying is employed to concentrate cross-linked MeHA in about 30% of the needle's height at the tip, thereby ensuring that only the TSMAP tip swells. Efficient MTX loading into TSMAP tips is achieved through a 30 s drug solution immersion and 10 min drying, potentially minimizing drug waste from incomplete skin insertion due to skin elasticity. The MTX-loaded TSMAP effectively penetrates both porcine and psoriasis-like mouse skin with its tips detaching from the resin substrate and embedding deeply into the skin tissue, thereby functioning as a drug release reservoir. TSMAP significantly prolongs drug retention in skin compared with SC injection and dissolvable microneedles. The in vivo study demonstrates that TSMAP-mediated MTX delivery substantially enhances therapeutic outcomes in alleviating psoriasis symptoms and downregulating psoriasis-associated cytokines, outperforming oral administration, SC injection, and dissolvable microneedles. Thus, TSMAP could offer an efficient and user-friendly alternative for drug administration in the treatment of various skin diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Psoriasis: Treatment and Pathogenesis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Materials Science and Engineering, Zhejiang University of Technology, Zhejiang, Hangzhou 310014, China
Hangzhou Institute of Medicine, Chinese Academy of Sciences, Zhejiang, Hangzhou 310022, China
College of Pharmaceutical Sciences, Zhejiang University of Technology, Zhejiang, Hangzhou 310014, China
Funding
National Natural Science Foundation of China · Hangzhou Institute of Medicine, Chinese Academy of Sciences · Medcraft Biotech. Inc.
References (41)
Show source-provided references
1. 10.1038/nrd160710.1038/nrd1607 ↗
2. 10.1016/j.jaad.2008.11.90610.1016/j.jaad.2008.11.906 ↗
3. 10.1016/j.jdcr.2022.02.03010.1016/j.jdcr.2022.02.030 ↗
4. 10.1111/ced.1510210.1111/ced.15102 ↗
5. 10.1007/s00431-018-3286-810.1007/s00431-018-3286-8 ↗
6. 10.1002/adma.20230241010.1002/adma.202302410 ↗
7. 10.1038/nrdp.2016.8210.1038/nrdp.2016.82 ↗
8. 10.1080/09546634.2020.177017010.1080/09546634.2020.1770170 ↗
9. 10.1007/s13346-023-01430-810.1007/s13346-023-01430-8 ↗
10. 10.1002/admt.20190055210.1002/admt.201900552 ↗
11. 10.1016/j.mattod.2022.10.02510.1016/j.mattod.2022.10.025 ↗
12. 10.1016/j.ijpharm.2023.12259110.1016/j.ijpharm.2023.122591 ↗
13. 10.1021/acsami.9b1566810.1021/acsami.9b15668 ↗
14. 10.1155/2022/696363010.1155/2022/6963630 ↗
15. 10.3390/pharmaceutics1501027710.3390/pharmaceutics15010277 ↗
16. 10.1016/j.ijpharm.2022.12161210.1016/j.ijpharm.2022.121612 ↗
17. 10.1007/BF0335378310.1007/BF03353783 ↗
18. 10.3389/fbioe.2023.111060410.3389/fbioe.2023.1110604 ↗
19. 10.1002/mabi.20230019410.1002/mabi.202300194 ↗
20. 10.1016/j.reactfunctpolym.2022.10520010.1016/j.reactfunctpolym.2022.105200 ↗
21. 10.1021/acs.nanolett.2c0225910.1021/acs.nanolett.2c02259 ↗
22. 10.1021/acsami.2c0535210.1021/acsami.2c05352 ↗
23. 10.1021/acs.molpharmaceut.0c0095410.1021/acs.molpharmaceut.0c00954 ↗
24. 10.1002/adhm.20230247010.1002/adhm.202302470 ↗
25. 10.1002/adma.20170224310.1002/adma.201702243 ↗
26. 10.1002/mabi.20230025310.1002/mabi.202300253 ↗
27. 10.1038/s41467-018-06981-w10.1038/s41467-018-06981-w ↗
28. 10.1021/acsami.2c1991310.1021/acsami.2c19913 ↗
29. 10.3390/pharmaceutics1109043210.3390/pharmaceutics11090432 ↗
30. 10.1002/btm2.1015710.1002/btm2.10157 ↗
31. 10.1002/btm2.1007010.1002/btm2.10070 ↗
32. 10.1126/sciadv.abe262010.1126/sciadv.abe2620 ↗
33. 10.1038/s41551-022-00998-910.1038/s41551-022-00998-9 ↗
34. 10.1016/j.jconrel.2022.04.04310.1016/j.jconrel.2022.04.043 ↗
35. 10.1038/s41577-018-0084-510.1038/s41577-018-0084-5 ↗
36. 10.1111/dth.1294310.1111/dth.12943 ↗
37. 10.1016/j.jconrel.2019.12.01610.1016/j.jconrel.2019.12.016 ↗
38. 10.1056/NEJMra080459510.1056/NEJMra0804595 ↗
39. 10.18632/oncotarget.2226010.18632/oncotarget.22260 ↗
40. 10.1155/2014/46754110.1155/2014/467541 ↗
41. 10.1155/MI.2005.27310.1155/MI.2005.273 ↗